Biomedical Engineering Reference
In-Depth Information
108. Urieto JO, Liu T, Black JH, Cohen KA, Hall PD, Willingham
MC, (2004) Expression and purification of the recombinant
diphtheria fusion toxin DT388IL3 for Phase I clinical trials.
Protein Expr. Purif. 33, 123-133.
109. Shaw JP, Akiyoshi DE, Arrigo DA, Rhoad AE, Sullivan B,
Thomas J, (1991) Cytotoxic properties of DAB486EGF and
DAB389EGF, epidermal growth factor (EGF) receptor-tar-
geted fusion toxins. J. Biol. Chem. 266, 21118-21124.
110. Frankel AE, Ramage J, Latimer A, Feely T, Delatte S, Hall P,
(1999) High-level expression and purification of the recom-
binant diphtheria fusion toxin DTGM for Phase I clinical
trials. Protein Expr. Purif. 16, 190-201.
111. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler
H, Willingham MC, (2007) Phase I study of SS1P, a
recombinant anti-mesothelin immunotoxin given as a bolus
I.V. infusion to patients with mesothelin-expressing meso-
thelioma, ovarian, and pancreatic cancers. Clin. Cancer Res.
13, 5144-5149.
112. Batra JK, FitzGerald D, Gately M, Chaudhary VK, Pastan I.
(1990) Anti-Tac(Fv)-PE40, a single chain antibody Pseudom-
onas fusion protein directed at interleukin 2 receptor bearing
cells. J. Biol. Chem. 265, 15198-15202.
113. Pai-Scherf LH, Villa J, Pearson D, Watson T, Liu E,
Willingham MC, (1999) Hepatotoxicity in cancer patients
receiving erb-38, a recombinant immunotoxin that targets the
erbB2 receptor. Clin. Cancer Res. 5, 2311-2315.
114. Reiter Y, Brinkmann U, Kreitman RJ, Jung SH, Lee B, Pastan
I. (1994) Stabilization of the Fv fragments in recombinant
immunotoxins by disulfide bonds engineered into conserved
framework regions. Biochemistry 33, 5451-5459.
115. Joshi BH, Puri RK. (2005) Optimization of expression and
purification of two biologically active chimeric fusion pro-
teins that consist of human interleukin-13 and Pseudomonas
exotoxin in Escherichia coli. Protein Expr. Purif. 39,
189-198.
116. Kreitman RJ, Pastan I. (1993) Purification and characteriza-
tion of IL6-PE4E, a recombinant fusion of interleukin 6 with
Pseudomonas exotoxin. Bioconjug. Chem. 4, 581-585.
117. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M,
Jaffe ES, Giardina S, (2000) Phase I trial of recombinant
immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with
hematologic malignancies. J. Clin. Oncol. 18, 1622-1636.
118. Edwards GM, DeFeo-Jones D, Tai JY, Vuocolo GA, Patrick
DR, Heimbrook DC, (1989) Epidermal growth factor receptor
binding is affected by structural determinants in the toxin
domain of transforming growth factor-alpha-Pseudomonas
exotoxin fusion proteins. Mol. Cell. Biol. 9, 2860-2867.
119. Mansfield E, Amlot P, Pastan I, FitzGerald DJ. (1997)
Recombinant RFB4 immunotoxins exhibit potent cytotoxic
activity for CD22-bearing cells and tumors. Blood 90,
2020-2026.
120. Alderson RF, Kreitman RJ, Chen T, Yeung P, Herbst R, Fox
JA, et al. (2009) CAT-8015: a second-generation pseudomo-
nas exotoxin A-based immunotherapy targeting CD22-
expressing hematologic malignancies. Clin. Cancer Res.
15, 832-839.
121. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I,
Puri RK. (2000) Intratumoral administration of recombinant
circularly permuted interleukin-4-Pseudomonas exotoxin
in patients with high-grade glioma. Clin. Cancer Res. 6,
2157-2165.
122. Debinski W, Puri RK, Kreitman RJ, Pastan I. (1993) A wide
range of human cancers express interleukin 4 (IL4) receptors
that can be targeted with chimeric toxin composed of IL4 and
Pseudomonas exotoxin. J. Biol. Chem. 268, 14065-14070.
123. Debinski W, Karlsson B, Lindholm L, Siegall CB,
Willingham MC, FitzGerald D, et al. (1992) Monoclonal
antibody C242-Pseudomonas exotoxin A. A specific and
potent immunotoxin with antitumor activity on a human colon
cancer xenograft in nude mice. J. Clin. Invest. 90, 405-411.
124. von Minckwitz G, Harder S, Hovelmann S, Jager E,
Al-Batran SE, Loibl S, et al. (2005) Phase I clinical study
of the recombinant antibody toxin scFv(FRP5)-ETA specific
for the ErbB2/HER2 receptor in patients with advanced solid
malignomas. Breast Cancer Res. 7, R617-626.
125. Altenschmidt U, Schmidt M, Groner B, Wels W. (1997)
Targeted therapy of schwannoma cells in immunocompetent
rats with an erbB2-specific antibody-toxin. Int. J. Cancer 73,
117-124.
126. Pastan IH, Archer GE, McLendon RE, Friedman HS, Fuchs
HE, Wang QC, et al. (1995) Intrathecal administration of
single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces
cures of carcinomatous meningitis in a rat model. Proc. Natl.
Acad. Sci. USA 92, 2765-2769.
127. Posey JA, Khazaeli MB, Bookman MA, Nowrouzi A, Grizzle
WE, Thornton J, et al. (2002) A Phase I trial of the single-
chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients
with advanced solid tumors. Clin. Cancer Res. 8, 3092-3099.
128. Friedman PN, McAndrew SJ, Gawlak SL, Chace D, Trail PA,
Brown JP, et al. (1993) BR96 sFv-PE40, a potent single-chain
immunotoxin that selectively kills carcinoma cells. Cancer
Res. 53, 334-339.
129. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid
E, et al. (2001) Pivotal Phase III trial of two dose levels of
denileukin diftitox for the treatment of cutaneous T-cell
lymphoma. J. Clin. Oncol. 19, 376-388.
130. Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y,
et al. (2010) Phase III placebo-controlled trial of denileukin
diftitox for patients with cutaneous T-cell lymphoma. J. Clin.
Oncol. 28, 1870-1877.
131. Rasku MA, Clem AL, Telang S, Taft B, Gettings K, Gragg H,
et al. (2008) Transient T cell depletion causes regression of
melanoma metastases. J. Transl. Med. 6, 12.
132. Dang NH, Pro B, Hagemeister FB, Samaniego F, Jones D,
Samuels BI, et al. (2007) Phase II trial of denileukin diftitox
for relapsed/refractory T-cell non-Hodgkin lymphoma. Br. J.
Haematol. 136, 439-447.
133. Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P,
FitzGerald DJ, Wilson WH, et al. (2005) Phase I trial of
recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in
patients with B-cell malignancies. J. Clin. Oncol. 23,
6719-6729.
Search WWH ::
Custom Search